Evidence-driven updates across biotech and AI

Articles, whitepapers and podcasts from our team and advisors.

December 9, 2025•External link

AI, LABI, and How we Invest: A Conversation with Neel Madhukar, PhD and Themasap Khan, PhD

Neel Madhukar, PhD, Chief Technology Officer of Luma Group’s proprietary AI model, LABI, discusses the genesis of the program and how it impacts day-to-day processes at Luma Group. Neel and Themasap discuss what we are building at Luma Group to change the game for biotech investing.

December 1, 2025

God Bless the Private Sector: How Private Funding is Bridging the Gap

Publicly funded basic research has long served as the foundation for breakthroughs. Yet proposed federal cuts, including reductions to the NSF and NIH, now threaten the early-stage research that the private sector traditionally does not fund. These changes have already stalled projects, eliminated jobs, and raised concerns about broader delays in scientific progress. At the same time, the United States faces intensifying competition with China, whose sustained investment in early-stage biotech has accelerated its global share of drug development. Although the US retains leadership in total R&D value, the trend signals growing vulnerability, one seemingly at odds with the administration’s broader “America First” agenda. The launch of the Genesis Mission, with its emphasis on AI-enabled science and biotechnology as a domain of national importance, hints at a potential restructuring rather than an abandonment of federal scientific priorities. In this environment, the private sector has emerged as an essential stabilizing force. As public funding recedes, venture capital and philanthropy must intervene earlier in the research lifecycle. This shift can bring rigorous private-sector diligence to basic science, likely focusing resources on fewer projects but with greater efficiency. To handle this complexity, biology-specific AI tools will shift from optional luxuries to indispensable necessities. Ultimately, this disruption offers a chance to modernize our infrastructure: building a resilient ecosystem capable of expanding, not just restoring, American scientific progress.

All Podcasts Whitepapers Articles

From Hippocrates to Hyperspeed: How AI Will Catalyze Advancements in Life Science

The AI revolution’s impact on society, particularly healthcare, is set to surpass the transformative effects of the Industrial and Information Revolutions. Real-world evidence of this can be seen in the application of AI-driven diagnostics and therapeutics, which have significantly enhanced the accuracy and speed of disease detection and rate of targeting and curing disease. The forthcoming role of AI in healthcare is ambitious yet achievable but requires a level of collaboration, innovation, and dedication to a brighter and healthier future.

Precision Therapy: Applying Proven Technologies to Inflammatory and Immunological Disease Treatment

The convergence of various factors, including advancements in OMIC data, repurposing of precision oncology technologies and high demand from patients and pharmaceutical companies, has positioned inflammation and immunology sectors for explosive growth, driving the development of safer and more effective precision therapies.